Quiz Ref ID The evidence underlying use of anticoagulant therapy for venous thromboembolism stems from a randomized clinical trial (RCT) in the 1960s
1 and subsequent uncontrolled studies demonstrating a reduction in the risk of recurrent venous thromboembolism. Recurrent venous thromboembolism encompasses deep vein thrombosis (DVT) and pulmonary embolism; recurrent DVT can increase the risk of chronic venous insufficiency (postthrombotic syndrome) and pulmonary embolism can be fatal.
2,3 Anticoagulant therapy for venous thromboembolism involves a trade-off between risks of recurrent venous thromboembolism and bleeding. As a statistical model for this trade-off, Kittelson et al
4-7 described a bivariate end point analytic approach, and applied this method to evaluate the net clinical benefit of antithrombotic therapies in RCTs.